Title: USE OF A COMPOSITION COMPRISING AN EXTRACT OF POLLEN FOR THE TREATMENT OF HORMONALLY-RELATED DISORDERS

Abstract: Use of a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils optionally combined with Royal Jelly and Vitamin E for manufacturing of a medicament for the treatment of disorders in relation to normal hormone variations in women of peri- and post-menopausal age.
USE OF A COMPOSITION COMPRISES AN EXTRACT OF POLLEN FOR THE TREATMENT OF HORMONALLY RELATED DISORDERS

FIELD OF THE INVENTION

The invention relates in a first aspect to a method for the treatment of disorders related to normal hormonal change in women in peri- and post-menopausal age, by the administering of a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils.

The invention, in another aspect, relates to the use of a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils for the manufacturing of a medicament for the treatment of disorders relating to normal hormonal change in women in peri- and post-menopausal age.

BACKGROUND OF THE INVENTION

Menopause, which is caused by a lowering of the production of female sex hormones at the age around 50, can to many women generate disorders such as hot flushes, attacks of sweating, muscle and possibly joint pain, sleep disturbances, dysphoria, nervousness, mood swings, headache, palpitations (enhanced frequency of heart rate), dry mucous membranes and pain during intercourse, urinary disturbances such as stress incontinence, frequent passing water and pain/irritability of the bladder and urethra during the process of passing water etc. All these disorders reflect age related hormonal changes which hitherto only have been alleviated effectively by the administration of female sex hormones like estrogen and the like.

Four out of five women have disturbing menopause disorders for at least one year and 25% of women have menopause disorders for more than 5 years. Half of all women have severe disorders and a population of 5 million inhabitants will constantly include about 200,000 women in the period of life where menopause trouble is disrupting their life.

Over the years different treatment options have been suggested to be effective for the treatment of the above-mentioned disorders. However few have shown a consistent efficacy on the majority thereof. The pharmacological treatments that have been tried include hormonal treatment as well as dietary interventions with e.g. vitamin and mineral supplementation, and natural products. Many of the compounds
used for the treatment are limited due to adverse effects. Therefore there remains a great need for safe compounds with a consistent efficacy.

A composition comprising an extract of combined pollen and pistils combined with a pollen grain extract, Royal Jelly and Vitamin E has been sold by Natumin Pharma AB, Kungsängsvägen 27, 561 56 Huskvarna, Sweden, for the treatment of Pre-Menstrual Syndrome (PMS).

SUMMARY OF THE INVENTION

The present inventors now have found that the administration of the present active composition, previously known only as a remedy to alleviate disorders related to PMS, provides a surprising and unexpected relief of disorders obstructing the normal life of women in the peri-and post-menopause without negative adverse effects.

The present inventors thus found an unexpected beneficial effect on disorders in relation to normal hormone variations in women of peri- and post-menopausal age, obtained by the administering of a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils, optionally in combination with Royal Jelly and Vitamin E.

The invention is based on this discovery.

The present invention provides a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils optionally combined with Royal Jelly and Vitamin E for manufacturing of a medicament for the treatment of disorders in relation to normal hormone variations in women of peri- and post-menopausal age.

In particular, the composition of the present invention is effective against such disorders as hot flashes, tendencies of sweating, palpitations, muscle pains, headache, difficulties in passing water, stress incontinence, dysphoria, dry vaginal and mucous membranes, arthralgia, water retention, irritability, and variations in mood.

The scope and preferred embodiments of the invention are as defined in the appended claims.
DETAILED DESCRIPTION OF THE INVENTION

The water-and/or fat-soluble cytosolic extract of pollen and optionally pistils preferably comprises an extract of pollen and pistils (PI 82) combined with an extract of pollen grain (GC FEM), as specified herein below. Both types of extract may be purchased from Allergon AB, Välingevägen 309, S-262 92 Ängelholm, Sweden, a Pharmacia company.

The pollens and pistils used for manufacturing of PI82 and GC FEM extracts are selected and harvested primarily from plants belonging to the grass family (Poaceae). During processing, treatment is performed on the pollen to open and remove the outer cell wall thereof as well as to minimize the risk of allergic pollen reactions.

PI 82 is a cytosolic pollen-pistil extract rich in superoxide dismutase (SOD) mimics. The source of PI 82 is freshly harvested pollen grains and pistils. The pollen and pistils are allowed to react under very specific conditions. In the reaction, the process of fertilization is initiated between pollen and pistils, and the extract comprises the product thereof. Substances obtained in this reaction are SOD mimics, flavonoids, tannins and polyphenols. In vitro studies have shown that the extract has high superoxide dismutase activity and prevents the formation of free radicals. Experiences from double blind patient investigation show that PI 82 protects the body from the negative influence of free radicals. Furthermore, PI 82 improves the red cell function, thus improving oxygen perfusion to different tissues.

GC FEM is a water-soluble cytosolic extract from pollen. The cytoplasm content of the pollen contains, in addition to the above-mentioned substances, a high amount of carbohydrates and protein. Furthermore, carotenoids and traces of estrogen substances are found. GC FEM contains natural bioflavonoids, vitamins, enzymes and trace elements.

Royal Jelly is a product of the processing of various plant materials within the salivary glands of the worker honeybees. It is rich in pantothenic acid (also called Vitamin B5), further vitamins and sterols. It is preferably included in the composition in lyophilized form, preferably concentrated by drying to a ratio of at least 1:3. Royal Jelly may be purchased from AB Montoil, Box 24150, S-104 51 Stockholm, Sweden.
As a source of Vitamin E, use is preferably made of Dry Vitamin E 50%, Type SD, from F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. Preferably dl-alpha-tocopherol is used, but other forms might also be valuable.

Further, common drug processing compounds may be included, such as diluents, glidants, lubricants, disintegrants, flavoring and coloring agents well known to the man skilled in the art of pharmaceutical sciences.

The active ingredients may be included in formulations of any form, such as tablets, powders, granules, and tinctures. They also may be included in foodstuff of different origin, e.g. as functional food. Administration to the woman in need thereof may take place several times a day, such as 1-8 times daily, 1-6 times daily or 1-4 times daily.

A daily dosage may contain from 60 to 960 mg of PI 82; from 18 to 288 mg of GC FEM; and optionally from 2 to 48 mg of Royal Jelly. Vitamin E might be included in an amount of from 5 to 80 mg.

Preferably, a daily dosage may contain from 60 to 480 mg of PI 82; from 20 to 140 mg of GC FEM; optionally from 2 to 30 mg of Royal Jelly; and optionally from 5 to 60 mg/day Vitamin E.

More preferably, a daily dosage may contain from 60 to 360 mg of PI 82, 20 to 80 mg of GC FEM, and optionally from 2 to 15 mg of Royal Jelly and optionally from 10 to 40 mg of Vitamin E.

Most preferably, a daily dosage may contain 240 mg PI 82, 72 mg of GC FEM and optionally 12 mg of Royal Jelly and optionally 20 mg of Vitamin E.

It should be noted that, unless no statement to the contrary is made, all amounts of Royal Jelly quoted herein refer to freeze-dried, i.e. lyophilized, Royal Jelly. The weight of Royal Jelly before freeze-drying is about at least three times higher, due to the water content of the same.

It furthermore should be noted that all the amounts of Vitamin E quoted herein refer to d-alpha-tocopherol, unless no statement to the contrary is made.
The remedy comprising the active ingredients should be administered to the woman in need thereof daily during at least one month, preferably at least two months.

Other excipients are included in amounts well known to any one skilled in the art of pharmaceutical sciences.

The mode of action is with present scientific knowledge not known. As the product contains three different natural constituents, each with a theoretically contributing effect, the combination of these may be a reason for the observed effect. The constituents Pl 82 and GC FEM contain SOD mimics such as flavonoids, tannins and polyphenols. These SOD mimics have an effect on free radical formation, which may be a factor involved in redistribution of fluids, including edema, seen under stress situation. An improved oxygen perfusion may also be a contributing effect.

Vitamin E is added to the composition as an active ingredient or as an antioxidant and stabilizer.

**Test of the effects on disorders relating to normal variations of the sex hormone pattern of women in the peri-and post-menopause**

**Test mode**
Ten women with an average age of 50.8 (range from 46 to 55) years were recruited for this open trial. All of them had been diagnosed to suffer from climacteric disorders. The menstruation had ceased for 5 women while being irregular for 5. None of the women were subject to any hormone therapy.

Each of the women obtained one tablet comprising the active ingredients in an amount of 120.0 mg Pl 82, 36.0 mg GC FEM, 6.0 mg Royal Jelly and 10.0 mg dl-alpha-tocopheryl acetate, twice daily, morning and evening. The treatment did not affect pulse, or systolic or diastolic blood pressure.

The investigated disorders, all relating to variations in the normal sex hormone pattern of women in the peri-and post-menopause, were menopausal hot flashes, tendencies of sweating, palpitations, sleep disorders, vertigo, muscle pains, headache, difficulties in passing water (pollakiuria), stress incontinence, dysphoria, dry-vaginal and mucous membranes, arthralgia, water retention (edema), irritability, and variations in mood.
Evaluation of the disorder was performed by use of a 10-cm VAS (visual analogous scale). Low values express favourable results. All statistical calculations are Wilcoxon test for matched pairs, if not otherwise stated. The results, illustrating the impact of active compositions on different menopausal disorders, are compiled in Table 1.
Mean value (standard deviation).

<table>
<thead>
<tr>
<th>Menopausal disorders</th>
<th>Without treatment (cm)</th>
<th>Treatment by active comp. 1 month (cm)</th>
<th>Treatment by active comp. 2 months (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hot flushes</td>
<td>3.08 (2.27)</td>
<td>2.81 (2.03)</td>
<td>1.33 (2.00)*</td>
</tr>
<tr>
<td>Sweating tendencies</td>
<td>3.94 (2.29)</td>
<td>2.75 (2.37)</td>
<td>1.73 (2.54)*</td>
</tr>
<tr>
<td>Palpitations</td>
<td>2.66 (2.74)</td>
<td>1.88 (1.37)</td>
<td>1.31 (1.66)*</td>
</tr>
<tr>
<td>Muscle pain</td>
<td>3.40 (3.19)</td>
<td>2.19 (1.42)</td>
<td>2.08 (2.40)**</td>
</tr>
<tr>
<td>Headache</td>
<td>3.77 (2.84)</td>
<td>2.38 (2.20)**</td>
<td>2.53 (1.98)**</td>
</tr>
<tr>
<td>Stress incontinence or frequent passing water</td>
<td>1.73 (2.34)</td>
<td>1.15 (1.44)</td>
<td>0.72 (0.85)*</td>
</tr>
<tr>
<td>Dysphoria</td>
<td>3.41 (2.05)</td>
<td>2.16 (1.27)*</td>
<td>1.60 (1.22)**</td>
</tr>
<tr>
<td>Dry vaginal and mucous membranes and/or pain</td>
<td>3.02 (2.88)</td>
<td>1.36 (1.31)**</td>
<td>1.52 (2.32)**</td>
</tr>
<tr>
<td>during intercourse</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint pain</td>
<td>3.94 (2.82)</td>
<td>1.91 (1.03)</td>
<td>1.48 (1.30)**</td>
</tr>
<tr>
<td>Mood</td>
<td>3.05 (2.26)</td>
<td>2.72 (1.90)</td>
<td>1.73 (1.15)</td>
</tr>
<tr>
<td>Edema</td>
<td>6.04 (2.53)</td>
<td>4.48 (1.93)*</td>
<td>3.28 (1.59)**</td>
</tr>
<tr>
<td>Energy loss</td>
<td>4.99 (2.15)</td>
<td>3.82 (1.60)*</td>
<td>2.72 (2.21)**</td>
</tr>
<tr>
<td>Irritability</td>
<td>3.18 (2.55)</td>
<td>2.20 (1.78)**</td>
<td>1.61 (1.24)*</td>
</tr>
<tr>
<td>Sleep disturbances</td>
<td>4.28 (3.89)</td>
<td>3.00 (3.07)</td>
<td>2.87 (3.09)</td>
</tr>
<tr>
<td>Mood swings</td>
<td>3.33 (2.16)</td>
<td>2.31 (1.07)</td>
<td>1.81 (1.63)*</td>
</tr>
<tr>
<td>Oversensitivity</td>
<td>4.03 (2.06)</td>
<td>2.70 (2.07)*</td>
<td>2.01 (1.79)**</td>
</tr>
</tbody>
</table>

# = borderline significance
* = p<0.05
** = p<0.02
*** = p<0.01
Hot flushes: significant (p <0.02) after two months.
Sweating tendencies: significant (p <0.05) after two months.
Palpitations: more than 50% reduction (borderline significant).
Muscle pains: significant (p <0.02) after one month and borderline after two months.
Headache: highly significant (p <0.01) after one and two months.
Stress incontinence and/or pollakiuria: reduction of about 60%, borderline significant.
Dysphoria: significant after one and two months (p <0.05 and p <0.02).
Dry vaginal or mucous membranes and/or pain during intercourse: significant after one and two months (p <0.01 and p <0.01) >50% reduction.
Joint pain: significant after two months (p <0.02)
Mood: not significant, however a favourable change of about 40% is obvious.
Edema/water retention: reduction of more than 50%, significant after one and two months (p <0.05 and p <0.02).
Energy loss: marked enhancement, significant after one and two months (p <0.05 and p <0.01).
Irritability: reduced by 50% (p <0.01 and p <0.05).
Sleep disturbances show a tendency of effect but is not significant.
Mood swings: borderline significant after two months.
Oversensitivity: significantly better after one and two months (p <0.05 and p <0.02).

If all VAS scores were added to a common “overall well-being score” a clearly positive effect is shown for 8 of 10 participants, only two were unchanged. Thus, the improvement is significant (p <0.02).

At a direct inquiry of all ten participants whether they have had any advantages or use of the treatment, 6 of them clearly said, “yes” while four answered “don’t know” (p <0.05, Chi square).

EXAMPLE

Below is given an Example of a tablet used according to the invention.

Active ingredients:
PI 82 (pollen-pistil extract) ................................................................. 120.0 mg
GC FEM (pollen extract) ........................................................................ 36.0 mg
Secondary ingredients:
ROYAL JELLY (freeze dried) ........................................... 6.0 mg
VITAMIN E 50% ................................................................. 20.0 mg

Other ingredients:
Microcrystalline cellulose ............................................. 87.0 mg
Dicalcium phosphate ...................................................... 87.0 mg
Magnesium stearate ...................................................... 4.0 mg

Uncoated tablet weight .................................................. 360.0 mg

Coating:
Shellac ................................................................. approx. 2.64 mg
Talc ................................................................. approx. 0.36 mg

Total weight ............................................................. approx. 363.0 mg
CLAIMS

1. Use of a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils, optionally combined with Royal Jelly and Vitamin E, for manufacturing of a medicament for the treatment of disorders in relation to normal hormone variations in women of peri- and post-menopausal age.

2. Use according to claim 1 wherein the water- and/or fat-soluble cytosolic extract is a combination of an extract of pollen and pistils, and an extract of pollen.

3. Use according to claim 2, wherein the extract of pollen and pistils is PI 82 and the extract of pollen is GC FEM.

4. Use according to claim 3 wherein the active ingredients are included in the medicament in amounts such as to give daily dosage of from 60 to 960 mg of PI 82; 18 to 288 mg of GC FEM; and optionally 2 to 48 mg of Royal Jelly and 5 to 80 mg of Vitamin E.

5. Use according to claim 4 wherein the active ingredients are included in the medicament in amounts such as to give daily dosage of from 60 to 480 mg of PI 82; 20 to 140 mg of GC FEM; and optionally 2 to 30 mg of Royal Jelly and 5 to 60 mg of Vitamin E.

6. Use according to claim 5 wherein the active ingredients are included in the medicament in amounts such as to give daily dosage of from 60 to 360 mg of PI 82; 20 to 80 mg of GC FEM; and optionally 2 to 15 mg of Royal Jelly and 10 to 40 mg of Vitamin E.

7. Use according to claim 6 wherein the active ingredients are included in the medicament in amounts such as to give daily dosage of 240 mg PI 82, 72 mg of GC FEM and optionally 12 mg of Royal Jelly and 20 mg of Vitamin E.

8. Use according to any of the claims 1-7, wherein the daily dosage of the medicament is administered in a single dose or in multiple doses, 1-8 times daily.
9. Use according to any of the above claims, wherein the disorders are selected from hot flashes, tendencies of sweating, palpitations, muscle pains, headache, difficulties in passing water, stress incontinence, dysphoria, dry vaginal and mucous membranes, arthralgia, water retention, irritability, and variations in mood.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC7: A61K 35/78, A61K 35/64, A61 31/355, A61P 15/12

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**WPI DATA, EPO INTERNAL, PAJ, BIOSIS, MEDLINE, EMBASE, NAPRALENT, CABA, IPA, CABHEALTH, PHAR, ESI, BIOBASE, MANTIS, GALE GROUP HEALTH & WELLNESS, Allied & Complementary Medicine**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 5569459 A (SHLYANKEVICH), 29 October 1996 (29.10.96), claims</td>
<td>1-9</td>
</tr>
<tr>
<td>Y</td>
<td></td>
<td>1-9</td>
</tr>
<tr>
<td>X</td>
<td>EP 1057483 A1 (TAIYO KAGAKU CO., LTD), 6 December 2000 (06.12.00), page 6, line 1 - line 5; page 6, line 33 - line 37, claim 2; page 7, lines 1 and 9</td>
<td>1-9</td>
</tr>
</tbody>
</table>

[X] Further documents are listed in the continuation of Box C.  
[X] See patent family annex.

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing data but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search: 17 January 2002

Date of mailing of the international search report: 18-01-2002

Name and mailing address of the ISA/Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer
Ida Christensen/BS
Telephone No. +46 8 782 25 00
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
Retrieved: 2001-04-19 | 1-9                  |
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 5569459 A</td>
<td>29/10/96</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>EP 1057483 A1</td>
<td>06/12/00</td>
<td>AU 2548899 A</td>
<td>06/09/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 1639165 C</td>
<td>18/02/92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3000306 B</td>
<td>07/01/91</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 60251077 A</td>
<td>11/12/85</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2000247878 A</td>
<td>12/09/00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2001089365 A</td>
<td>03/04/01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 201001307 A</td>
<td>17/05/01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9942096 A</td>
<td>26/08/99</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2001089364 A</td>
<td>03/04/01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2000053568 A</td>
<td>22/02/00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2000143508 A</td>
<td>23/05/00</td>
</tr>
</tbody>
</table>